Tailoring adjuvant treatment in patients with uterine cancer - Authors' reply

Affiliations

¹ The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: mfrumovitz@mdanderson.org.
² Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Comment

Michael Frumovitz et al. Lancet Oncol. 2018 Dec.

. 2018 Dec;19(12):e656.

doi: 10.1016/S1470-2045(18)30832-5.

¹ The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: mfrumovitz@mdanderson.org.
² Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

No abstract available

Comment on

Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial.
Frumovitz M, Plante M, Lee PS, Sandadi S, Lilja JF, Escobar PF, Gien LT, Urbauer DL, Abu-Rustum NR. Frumovitz M, et al. Lancet Oncol. 2018 Oct;19(10):1394-1403. doi: 10.1016/S1470-2045(18)30448-0. Epub 2018 Aug 22. Lancet Oncol. 2018. PMID: 30143441 Free PMC article. Clinical Trial.
Tailoring adjuvant treatment in patients with uterine cancer.
Bogani G, Chiappa V, Lorusso D, Raspagliesi F. Bogani G, et al. Lancet Oncol. 2018 Dec;19(12):e655. doi: 10.1016/S1470-2045(18)30684-3. Lancet Oncol. 2018. PMID: 30507415 No abstract available.